StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

TG Therapeutics's price to sales ratio was 12.6× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 7.6× to 493.1×, with a median of 14.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.6×+3.9
2025Dec 31, 20258.7×−9.0
2024Dec 31, 202417.7×+4.1
2023Dec 29, 202313.6×−328.6
2022Dec 30, 2022342.2×−150.9
2021Nov 30, 2021493.1×–

More TG Therapeutics figures

See a number that looks wrong?